Antineoplastic Agents, Immunological
- Antineoplastic Agents, Immunological
- Accession Number
Monoclonal antibodies that inhibit or prevent the proliferation of NEOPLASMS.
Drug Drug Description Cetuximab An endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck. Trastuzumab A monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers. Alemtuzumab A monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis. Bevacizumab A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer. Panitumumab A recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens. Epratuzumab Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus. Oregovomab Investigated for use/treatment in ovarian cancer. Labetuzumab Labetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab" Bavituximab Investigated for use/treatment in breast cancer, cancer/tumors (unspecified), HIV infection, hepatitis (viral, C), and solid tumors. Rindopepimut Investigated for use/treatment in brain cancer. Trastuzumab emtansine An antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer. CT-011 Investigated for use/treatment in cancer/tumors (unspecified). Glembatumumab vedotin Investigated for use/treatment in melanoma. Ipilimumab A human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. Nimotuzumab An EGFR-targeting monoclonal antibody used in the treatment of squamous cell carcinomas of the head and neck and glioblastomas. Pertuzumab An antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents. Obinutuzumab An antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil. Nivolumab A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. Pembrolizumab A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. Necitumumab A monoclonal antibody used to treat metastatic squamous non-small cell lung cancer. Conatumumab Conatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others. Durvalumab An antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer. Rilotumumab Rilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others. Zalutumumab Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell... Dacetuzumab Investigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma. Intetumumab Intetumumab has been used in trials studying the treatment of Melanoma. Ecromeximab Ecromeximab has been used in trials studying the treatment of Cutaneous Melanoma and Metastatic Melanoma. Talimogene laherparepvec A genetically modified virus used to treat recurrent melanoma, or metastatic melanoma. Cemiplimab A programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer. Lintuzumab Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia). Pidilizumab Pidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma). Abagovomab Abagovomab is under investigation in clinical trial NCT00418574 (Efficacy Multicentre Trial of Immunotherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients). Magrolimab Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer). Tisotumab vedotin A tissue factor-directed antibody drug conjugate that is used to treat adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Brentuximab vedotin A CD30-directed antibody-drug conjugate used to treat various types of lymphoma. Avelumab A monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma. Tisagenlecleucel A CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma. Axicabtagene ciloleucel A CAR T-cell therapy used to treat adults with large B-cell lymphomas and follicular lymphoma. Idecabtagene vicleucel An autologous T-cell therapy indicated to treat relapsed or refractory multiple myeloma. Amivantamab An EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation. Gemtuzumab ozogamicin A monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia. Rituximab A monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis. Inotuzumab ozogamicin An antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL). Lorvotuzumab mertansine Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others. Tislelizumab Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors). Brexucabtagene autoleucel A modified autologous chimeric antigen receptor (CAR) T cell therapy employing a modified murine anti-CD19 single-chain variable fragment linked to CD28 and CD3ζ co-stimulatory domains for the treatment of patients with relapsed and refractory mantle cell lymphoma. Bemarituzumab Bemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)). Loncastuximab tesirine An antibody-drug conjugate used for the treatment of relapsed and refractory B-cell lymphomas. Abatacept A disease-modifying antirheumatic drug (DMARD) used in the management of rheumatic conditions, such as rheumatoid or psoriatic arthritis, and for the prophylaxis of acute graft-versus-host disease. Belatacept A selective T-cell costimulation blocker used in the prophylaxis of organ rejection in adult patients receiving a kidney transplant. Spartalizumab Spartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma). Sotorasib An experimental KRAS inhibitor being investigated for the treatment of KRAS G12C mutant non small cell lung cancer, colorectal cancer, and appendix cancer. Cantuzumab mertansine Not Annotated BI 836826 Not Annotated Zanolimumab Zanolimumab is a fully human monoclonal antibody directed against CD4. Adagrasib A KRAS inhibitor indicated for the treatment of locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer in patients who have received at least one prior systemic therapy.
- Drugs & Drug Targets